Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/21610
Title: | The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses | Authors: | VANMIERLO, Tim Creemers, Pim Akkerman, Sven van Duinen, Marlies Sambeth, Anke DE VRY, Jochen Uz, Tolga Blokland, Arjan Prickaerts, Jos |
Issue Date: | 2016 | Publisher: | ELSEVIER SCIENCE BV | Source: | BEHAVIOURAL BRAIN RESEARCH, 303, p. 26-33 | Abstract: | Enhancement of central availability of the second messenger CAMP is a promising approach to improve cognitive function. Pharmacological inhibition of phosphodiesterase type 4 (PDE4), a group of cAMP hydrolyzing enzymes in the brain, has been shown to improve cognitive performances in rodents and monkeys. However, inhibition of PDE4 is generally associated with severe emetic side-effects. Roflumilast, an FDA-approved PDE4 inhibitor for treatment of chronic obstructive pulmonary disease (COPD), is yielding only mild emetic side effects. In the present study we investigate the potential of roflumilast as a cognition enhancer and to determine the potential coinciding emetic response in comparison to rolipram, a classic PDE4 inhibitor with pronounced emetic effects. Cognition enhancement was evaluated in mice and it was found that both roflumilast and rolipram enhanced memory in an object location task (0.03 mg/kg), whereas only roflumilast was effective in a spatial Y-maze (0.1 mg/kg). Emetic potential was measured using competition of PDE4 inhibition for alpha 2-adrenergic receptor antagonism in which recovery from xylazine/ketamine-mediated anesthesia is used as a surrogate marker. While rolipram displayed emetic properties at a dose 10 times the memory-enhancing dose, roflumilast only showed increased emetic-like properties at a dose 100 times the memory-enhancing dose. Moreover, combining sub-efficacious doses of the approved cognition enhancer donepezil and roflumilast, which did not improve memory when given alone, fully restored object recognition memory deficit in rats induced by the muscarinic receptor antagonist scopolamine. These findings suggest that roflumilast offers a more favorable window for treatment of cognitive deficits compared to rolipram. (C) 2016 Elsevier B.V. All rights reserved. | Notes: | [Vanmierlo, Tim; Creemers, Pim; Akkerman, Sven; van Duinen, Marlies; De Vry, Jochen; Prickaerts, Jos] Maastricht Univ, Sch Mental Hlth & Neurosci, Dept Psychiat & Neuropsychol, POB 616, NL-6200 MD Maastricht, Netherlands. [Vanmierlo, Tim] Hasselt Univ, BIOMED, Dept Immunol & Biochem, Hasselt, Belgium. [Sambeth, Anke; Blokland, Arjan] Maastricht Univ, Dept Neuropsychol & Psychopharmacol, NL-6200 MD Maastricht, Netherlands. [Uz, Tolga] Takeda Dev Ctr Amer Inc, Expt Med CNS, Deerfield, IL USA. [Creemers, Pim] Boston Sci Grp Plc, Dept Neuromodulat, Clin, Maastricht, Netherlands. | Keywords: | PDE4; PDE4 inhibition; roflumilast; rolipram; cognition; memory; emesis; cAMP;PDE4; PDE4 inhibition; Roflumilast; Rolipram; Cognition; Memory; Emesis; cAMP | Document URI: | http://hdl.handle.net/1942/21610 | ISSN: | 0166-4328 | e-ISSN: | 1872-7549 | DOI: | 10.1016/j.bbr.2016.01.031 | ISI #: | 000372688900004 | Rights: | © 2016 Elsevier B.V. All rights reserved. | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2017 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
vanmierlo 1.pdf Restricted Access | Published version | 1.08 MB | Adobe PDF | View/Open Request a copy |
PDE4.pdf | Peer-reviewed author version | 796.57 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
41
checked on Sep 5, 2020
WEB OF SCIENCETM
Citations
88
checked on Oct 14, 2024
Page view(s)
82
checked on Sep 7, 2022
Download(s)
410
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.